India’s Affordable Medicines Under Threat In Asian RCEP Talks?
This article was originally published in PharmAsia News
India needs to take a strong stand in Asian free trade negotiations against calls for tougher intellectual property rules that could harm access to affordable medicines for millions of patients around the globe, says Médecins Sans Frontières.
You may also be interested in...
Humanitarian group MSF says India is facing “pincer-like pressure” to relax its strict patent laws in order to conclude free trade deals in Europe and Asia, and is calling on New Delhi to stand firm.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.